Maynard Um
-
-
-
-
-
-
-
AnaptysBio (ANAB) Reiterated at Buy by UBS: Trial Now Set for July 2026
-
-
-
-
-
-
-
AnaptysBio files lawsuit against Tesaro and GSK over license deal
-
-
-
-
-
-
-
AnaptysBio to present rosnilimab rheumatoid arthritis data at ACR meeting
-
-
-
-
-
-
-
Anaptys plans split into royalty and biopharma companies by 2026
-
-
-
-
-
-
-
Anaptysbio (ANAB) Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
-
-
-
-
-
-
-
AnaptysBio (ANAB) PT Raised to $52 at Guggenheim
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) and Anaptys (ANAB) Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

